Results 171 to 180 of about 8,652,661 (302)

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

open access: yesMolecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker   +16 more
wiley   +1 more source

Ultrafast Synthesis of Large‐Sized and Conductive Na3V2(PO4)2F3 Simultaneously Approaches High Tap Density, Rate and Cycling Capability [PDF]

open access: bronze
Zijing Song   +13 more
openalex   +1 more source

The ubiquitin ligase HACE1 regulates Golgi membrane dynamics during the cell cycle [PDF]

open access: bronze, 2011
Danming Tang   +6 more
openalex   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

open access: yesMolecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande   +11 more
wiley   +1 more source

Organic rankine cycle versus steam cycle : a thermodynamic comparison [PDF]

open access: yes, 2012
De Paepe, Michel   +2 more
core   +1 more source

Loss of integrin α3 prevents skin tumor formation by promoting epidermal turnover and depletion of slow-cycling cells [PDF]

open access: bronze, 2012
Norman Sachs   +5 more
openalex   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

open access: yesMolecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy